Hepatology:低血清铁调节蛋白与急性肝衰竭患者短期存活率降低有关

2019-04-20 不详 MedSci原创

肝脏可以通过合成血清转运蛋白和铁调节蛋白参与体内铁稳态的维持,因此肝脏铁稳态调节中具有重要作用。因此,本研究的目的是分析成人急性肝衰竭(ALF)和由乙酰氨基酚(APAP)诱导的ALF衷铁代谢的情况。

背景及目的:
肝脏可以通过合成血清转运蛋白和铁调节蛋白参与体内铁稳态的维持,因此肝脏铁稳态调节中具有重要作用。因此,本研究的目的是分析成人急性肝衰竭(ALF)和由乙酰氨基酚(APAP)诱导的ALF衷铁代谢的情况。

方法及结果:
研究人员共纳入121名患有ALF的成人(包括66名APAP相关患者)进行铁蛋白,转铁蛋白,铁和铁调节蛋白的检测。入组后3周的结果分为自发幸存者(SS)与死亡/移植(NSS)者。同时,在小鼠中注射300mg / kg APAP,以评估对照和注射后4和18小时小鼠的肝脏状况。ALF患者以及APAP治疗的小鼠显示出铁蛋白增加和血清铁调素和铁调节蛋白/铁蛋白比率降低。(P  <0.05),但铁调节蛋白水平较高(8.2 VS 2.7 ng / mL; P  <0.001)。在多变量分析中,对数转化的含铁调素的模型显示出与建立的急性肝衰竭研究组指数相似的预后能力(C-Index=0.87 VS 0.85),并且优于终末期肝病评分模型(C-Index=0.76)。在小鼠中,铁调节蛋白水平与肝损伤的替代品呈负相关关系。

结论:
本项研究结果表明,几种血清铁参数与ALF成人的3周结果显着相关。其中,铁调节蛋白在实验性APAP诱导的ALF中早期呈降低,是一个独立的预测因子。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635815, encodeId=0a5e163581559, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Sat Dec 14 20:48:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862944, encodeId=825818629446d, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Sep 11 09:48:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004088, encodeId=fee0200408890, content=<a href='/topic/show?id=17a9894e3e5' target=_blank style='color:#2F92EE;'>#血清铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89473, encryptionId=17a9894e3e5, topicName=血清铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Tue Apr 23 04:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290486, encodeId=3194129048627, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427318, encodeId=475c142e318f3, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635815, encodeId=0a5e163581559, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Sat Dec 14 20:48:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862944, encodeId=825818629446d, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Sep 11 09:48:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004088, encodeId=fee0200408890, content=<a href='/topic/show?id=17a9894e3e5' target=_blank style='color:#2F92EE;'>#血清铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89473, encryptionId=17a9894e3e5, topicName=血清铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Tue Apr 23 04:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290486, encodeId=3194129048627, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427318, encodeId=475c142e318f3, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1635815, encodeId=0a5e163581559, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Sat Dec 14 20:48:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862944, encodeId=825818629446d, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Sep 11 09:48:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004088, encodeId=fee0200408890, content=<a href='/topic/show?id=17a9894e3e5' target=_blank style='color:#2F92EE;'>#血清铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89473, encryptionId=17a9894e3e5, topicName=血清铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Tue Apr 23 04:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290486, encodeId=3194129048627, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427318, encodeId=475c142e318f3, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-23 mnda
  4. [GetPortalCommentsPageByObjectIdResponse(id=1635815, encodeId=0a5e163581559, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Sat Dec 14 20:48:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862944, encodeId=825818629446d, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Sep 11 09:48:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004088, encodeId=fee0200408890, content=<a href='/topic/show?id=17a9894e3e5' target=_blank style='color:#2F92EE;'>#血清铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89473, encryptionId=17a9894e3e5, topicName=血清铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Tue Apr 23 04:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290486, encodeId=3194129048627, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427318, encodeId=475c142e318f3, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1635815, encodeId=0a5e163581559, content=<a href='/topic/show?id=9e5781499dd' target=_blank style='color:#2F92EE;'>#肝衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81499, encryptionId=9e5781499dd, topicName=肝衰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fedc22527786, createdName=1249884fm94暂无昵称, createdTime=Sat Dec 14 20:48:00 CST 2019, time=2019-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862944, encodeId=825818629446d, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Sep 11 09:48:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004088, encodeId=fee0200408890, content=<a href='/topic/show?id=17a9894e3e5' target=_blank style='color:#2F92EE;'>#血清铁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89473, encryptionId=17a9894e3e5, topicName=血清铁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Tue Apr 23 04:48:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290486, encodeId=3194129048627, content=<a href='/topic/show?id=fb34523817d' target=_blank style='color:#2F92EE;'>#急性肝衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52381, encryptionId=fb34523817d, topicName=急性肝衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427318, encodeId=475c142e318f3, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Apr 22 06:48:00 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-22 gwc384

相关资讯

Br J Nutr:黑豆皮可通过抑制Hepcidin改善贫血

   我国科学家的一项研究发现,黑豆皮提取物能够提高机体对铁元素的吸收,带皮食用黑豆能够改善贫血症状,同时,这项研究为研发安全、高效的药物来治疗贫血提供了一条新途径。 这一研究成果来自于浙江大学公共卫生学院王福娣教授团队。他们发现,黑豆皮提取物的补血作用通过作用于人体内的“铁调素”(Hepcidin)而达成。 铁调素是由肝脏产生的一种调节分子,是调节人体铁稳